Nothing Special   »   [go: up one dir, main page]

SG11201706583PA - Anti-pvrig antibodies and methods of use - Google Patents

Anti-pvrig antibodies and methods of use

Info

Publication number
SG11201706583PA
SG11201706583PA SG11201706583PA SG11201706583PA SG11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA SG 11201706583P A SG11201706583P A SG 11201706583PA
Authority
SG
Singapore
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
SG11201706583PA
Inventor
Mark White
Sandeep Kumar
Christopher Chan
Spencer Liang
Lance Stapleton
Andrew W Drake
Yosi Gozlan
Iian Vaknin
Shirley Sameah-Greenwald
Liat Dassa
Zohar Tiran
Gad S Cojocaru
Leonard Presta
Richard Theolis
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706583P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of SG11201706583PA publication Critical patent/SG11201706583PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
SG11201706583PA 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use SG11201706583PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01
PCT/US2016/018809 WO2016134333A1 (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11201706583PA true SG11201706583PA (en) 2017-09-28

Family

ID=55453315

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706583PA SG11201706583PA (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Country Status (23)

Country Link
US (7) US10227408B2 (en)
EP (4) EP3295951B1 (en)
JP (2) JP7115856B2 (en)
KR (2) KR20240090732A (en)
CN (2) CN115350275A (en)
AU (3) AU2016219835B2 (en)
CA (1) CA2976926A1 (en)
CY (2) CY1122970T1 (en)
DK (3) DK3653221T5 (en)
ES (3) ES2786651T3 (en)
HK (2) HK1247569A1 (en)
HR (3) HRP20221284T1 (en)
HU (3) HUE049791T2 (en)
IL (2) IL254039B2 (en)
LT (3) LT3295951T (en)
MX (2) MX2017010667A (en)
PL (3) PL3295951T3 (en)
PT (3) PT3258951T (en)
RU (1) RU2732042C2 (en)
SG (1) SG11201706583PA (en)
SI (2) SI3295951T1 (en)
WO (1) WO2016134333A1 (en)
ZA (1) ZA201706323B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
DK3259597T3 (en) 2015-02-19 2022-05-09 Compugen Ltd PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
EP3295951B1 (en) 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CN111234027A (en) 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
US11078278B2 (en) * 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
WO2017040301A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
CA2997179A1 (en) * 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3617232A1 (en) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP6866475B2 (en) 2016-09-23 2021-04-28 フレッド ハッチンソン キャンサー リサーチ センター Minor histocompatibility (H) TCR specific for antigen HA-1 and its use
MX2019010972A (en) 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof.
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN113896792A (en) 2017-05-12 2022-01-07 哈普恩治疗公司 Mesothelin binding proteins
US11576933B2 (en) 2017-05-24 2023-02-14 Effector Therapeutics Inc. Compositions and methods for an improved antitumor immune response
MX2019014265A (en) 2017-06-01 2020-08-03 Compugen Ltd Triple combination antibody therapies.
MA49652A (en) * 2017-07-17 2020-05-27 Janssen Biotech Inc ANTIGEN-BINDING REGIONS DIRECTED TO FIELDS OF FIBRONECTIN TYPE III AND THEIR METHODS OF USE
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
US20200262894A1 (en) 2017-09-06 2020-08-20 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
EP3679072A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
KR20220111743A (en) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B cell maturation antigen binding proteins
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US11919960B2 (en) 2018-03-13 2024-03-05 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
US12077583B2 (en) 2018-05-09 2024-09-03 Nectin Therapeutics Ltd. Antibodies specific to human NECTIN4
KR102480815B1 (en) 2018-05-31 2022-12-26 글라이코넥스 인코포레이티드 Therapeutic antibodies that bind to biantennary Lewis B and Lewis Y antigens
EP3802605A1 (en) * 2018-06-01 2021-04-14 Compugen Ltd. Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CN112584865A (en) 2018-07-20 2021-03-30 表面肿瘤学公司 anti-CD 112R compositions and methods
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20210340201A1 (en) 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
EP3849610A4 (en) * 2018-09-14 2022-12-07 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3119188A1 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
ES2961791T3 (en) 2018-12-19 2024-03-13 Humabs Biomed Sa Antibodies that neutralize the hepatitis B virus and their uses
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
JP7492522B2 (en) * 2019-02-06 2024-05-29 パイオニア イミュノセラピューティクス インコーポレイテッド Anti-TREM1 Antibodies and Related Methods
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CN113784978A (en) 2019-03-11 2021-12-10 弗雷德哈钦森癌症研究中心 High affinity WT 1T cell receptor and uses thereof
WO2021021837A2 (en) 2019-07-29 2021-02-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3147717A1 (en) 2019-08-20 2021-02-25 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
MX2022002231A (en) 2019-08-29 2022-03-22 Vir Biotechnology Inc Antibody compositions and methods for treating hepatitis b virus infection.
CA3160162A1 (en) 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
CN114746116A (en) * 2019-11-15 2022-07-12 表面免疫肿瘤学公司 Compositions and methods for immunotherapy
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
EP4119162A4 (en) * 2020-03-13 2023-08-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
WO2021262840A1 (en) 2020-06-24 2021-12-30 Vir Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
KR20230035576A (en) 2020-07-07 2023-03-14 비온테크 에스이 RNA for the treatment of HPV-positive cancer
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
CN116724053A (en) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 Immunotherapy targeting SOX2 antigen
JP2023552034A (en) * 2020-09-25 2023-12-14 蘇州爾生生物医薬有限公司 Method for detecting tumor-specific T cells
TW202222841A (en) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 Compositions and methods for treating mage-a1-expressing disease
WO2022090801A2 (en) * 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (en) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 Method for detecting biological activity of PVRIG antibody based on reporter gene method
EP4259651A2 (en) 2020-12-14 2023-10-18 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
EP4284428A1 (en) 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2022165275A2 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
EP4284516A1 (en) * 2021-01-28 2023-12-06 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
EP4292611A1 (en) * 2021-02-09 2023-12-20 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
EP4291580A1 (en) 2021-02-11 2023-12-20 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
CN115925917A (en) 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 anti-PVRIG protein antibodies or antibody fragments and uses thereof
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
WO2022258049A1 (en) * 2021-06-10 2022-12-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric pvrig
EP4363450A1 (en) * 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023288281A2 (en) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Chimeric polypeptides
JP2024530451A (en) 2021-07-30 2024-08-21 山▲東▼先声生物制▲薬▼有限公司 Anti-PVRIG/anti-TIGIT bispecific antibodies and applications
JP2024535768A (en) 2021-09-15 2024-10-02 江蘇恒瑞医薬股▲ふん▼有限公司 Pharmaceutical compositions comprising anti-PVRIG/TIGIT bispecific antibodies
TW202327649A (en) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Pvrig/tigit binding proteins in combination with immune checkpoint inhibitors for the treatment of cancer
CA3231320A1 (en) 2021-09-15 2023-03-23 Zhiliang CAO Protein specifically binding to pd-1 and pharmaceutical use thereof
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN114644711A (en) * 2022-03-07 2022-06-21 南京诺艾新生物技术有限公司 Recombinant anti-human PVRIG antibody and application thereof
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
US20240103010A1 (en) * 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116925233A (en) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 anti-TIGIT-anti-PVRIG bispecific antibody, pharmaceutical composition and use thereof
CN116925222A (en) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 anti-PVRIG antibody, pharmaceutical composition and application thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AR129399A1 (en) 2022-05-23 2024-08-21 Vir Biotechnology Inc DESIGNED ANTIBODIES NEUTRALIZING HEPATITIS B VIRUS AND THEIR USES
TW202415678A (en) * 2022-06-14 2024-04-16 比利時商艾伯霖克斯公司 Immunoglobulin single variable domains targeting t cell receptor
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2024032700A1 (en) * 2022-08-10 2024-02-15 Beigene, Ltd. Anti-pvrig antibodies and methods of use
CN117957254A (en) * 2022-08-31 2024-04-30 石药集团巨石生物制药有限公司 Anti-PVRIG antibodies and uses thereof
WO2024098980A1 (en) * 2022-11-10 2024-05-16 Huahui Health Ltd. Anti-cd112r antibodies and use thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2156149T3 (en) 1992-12-04 2001-06-16 Medical Res Council MULTIVALENT AND MULTI-SPECIFIC UNION PROTEINS, ITS MANUFACTURE AND USE.
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (en) 1998-04-20 2010-04-01 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODY-DEPENDENT CELL-EMITTED CYTOTOXICITY
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR20060067983A (en) 1999-01-15 2006-06-20 제넨테크, 인크. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000052151A2 (en) 1999-03-05 2000-09-08 Incyte Pharmaceuticals, Inc. Human secretory proteins
DK2270147T4 (en) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
CA2446458A1 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003270439B2 (en) 2002-09-11 2009-09-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003290432A1 (en) 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
KR101208291B1 (en) 2003-04-04 2012-12-05 노파르티스 아게 High concentration antibody and protein formulations
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
ES2772674T3 (en) 2005-05-12 2020-07-08 Zymogenetics Inc Compositions and methods for modulating immune responses
AU2007240491A1 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
US20070243584A1 (en) 2006-04-13 2007-10-18 West James W Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
JPWO2008044754A1 (en) * 2006-10-06 2010-02-18 武田薬品工業株式会社 Cancer preventive / therapeutic agent
US8344112B2 (en) * 2007-07-31 2013-01-01 Merck Sharp & Dohme Limited IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CA2719189C (en) 2008-04-09 2020-08-04 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CN102308212A (en) 2008-12-04 2012-01-04 加利福尼亚大学董事会 Materials and methods for determining diagnosis and prognosis of prostate cancer
US9315584B2 (en) 2009-03-25 2016-04-19 Tohoku University LH-type bispecific antibody
TW201132813A (en) 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
WO2012178128A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
MX2014014951A (en) * 2012-06-06 2015-03-13 Oncomed Pharm Inc Binding agents that modulate the hippo pathway and uses thereof.
CN103073644B (en) 2012-12-31 2014-03-12 中国科学技术大学 Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof
EP3789036A1 (en) 2013-07-16 2021-03-10 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
NZ729162A (en) 2014-08-19 2024-08-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
EP3295951B1 (en) 2015-02-19 2020-04-22 Compugen Ltd. Anti-pvrig antibodies and methods of use
DK3259597T3 (en) 2015-02-19 2022-05-09 Compugen Ltd PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
TWI715587B (en) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (en) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
AU2016325610B2 (en) 2015-09-25 2019-10-10 Genentech, Inc. Anti-TIGIT antibodies and methods of use
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
EP3617232A1 (en) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof

Also Published As

Publication number Publication date
EP3258951A1 (en) 2017-12-27
JP2018512443A (en) 2018-05-17
JP7115856B2 (en) 2022-08-09
US20160244521A1 (en) 2016-08-25
HK1247569A1 (en) 2018-09-28
KR20240090732A (en) 2024-06-21
US20210188974A1 (en) 2021-06-24
EP3295951B1 (en) 2020-04-22
CN107580500A (en) 2018-01-12
DK3295951T3 (en) 2020-07-20
ES2786651T3 (en) 2020-10-13
PT3295951T (en) 2020-07-21
US11220542B2 (en) 2022-01-11
LT3295951T (en) 2020-09-25
WO2016134333A9 (en) 2017-02-02
ES2806800T3 (en) 2021-02-18
RU2017132214A3 (en) 2019-08-28
MX2020009461A (en) 2021-02-17
MX2017010667A (en) 2018-08-15
RU2020128686A (en) 2020-10-13
DK3258951T3 (en) 2020-04-06
DK3653221T3 (en) 2022-10-24
EP3258951B1 (en) 2020-01-29
US10351625B2 (en) 2019-07-16
HRP20200572T1 (en) 2020-08-21
HUE049032T2 (en) 2020-08-28
AU2016219835A1 (en) 2017-09-14
PT3653221T (en) 2022-11-08
PT3258951T (en) 2020-08-18
LT3258951T (en) 2020-05-11
EP3653221B1 (en) 2022-08-03
RU2017132214A (en) 2019-03-19
US20180244774A1 (en) 2018-08-30
AU2020264349A1 (en) 2020-12-03
SI3295951T1 (en) 2020-10-30
EP3295951A1 (en) 2018-03-21
KR102669294B1 (en) 2024-05-23
CA2976926A1 (en) 2016-08-25
IL254039B2 (en) 2023-12-01
SI3258951T1 (en) 2020-07-31
HUE061084T2 (en) 2023-05-28
ES2929293T3 (en) 2022-11-28
LT3653221T (en) 2022-11-10
US20170029504A1 (en) 2017-02-02
CN107580500B (en) 2023-05-30
CN115350275A (en) 2022-11-18
JP2022106783A (en) 2022-07-20
EP3653221A1 (en) 2020-05-20
DK3653221T5 (en) 2024-08-26
HRP20221284T1 (en) 2022-12-23
US11623955B2 (en) 2023-04-11
HK1247568A1 (en) 2018-09-28
US20200148769A1 (en) 2020-05-14
US20240101669A1 (en) 2024-03-28
KR20170137067A (en) 2017-12-12
ZA201706323B (en) 2020-05-27
AU2016219835B2 (en) 2020-12-03
IL304117A (en) 2023-09-01
IL254039B1 (en) 2023-08-01
US9714289B2 (en) 2017-07-25
PL3295951T3 (en) 2020-10-05
WO2016134333A1 (en) 2016-08-25
US11795220B2 (en) 2023-10-24
US10227408B2 (en) 2019-03-12
PL3653221T3 (en) 2022-12-19
CY1122970T1 (en) 2021-10-29
AU2020264349B2 (en) 2024-05-02
AU2024202336A1 (en) 2024-05-16
CY1123259T1 (en) 2021-12-31
HUE049791T2 (en) 2020-10-28
PL3258951T3 (en) 2020-07-27
IL254039A0 (en) 2017-10-31
RU2732042C2 (en) 2020-09-10
US20170081408A1 (en) 2017-03-23
HRP20201066T1 (en) 2021-02-05
EP4129320A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (en) Anti-tigit antibodies and methods of use
HK1252858A1 (en) Anti-cll-1 antibodies and methods of use
HK1249445A1 (en) Anti-sortilin antibodies and methods of use thereof
HK1252698A1 (en) Anti-siglec-9 antibodies and methods of use thereof
IL259495A (en) Antibodies and methods of use thereof
HK1252696A1 (en) Anti-siglec-7 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL270793A (en) Anti-htra1 antibodies and methods of use thereof
HK1258850A1 (en) Anti-tpbg antibodies and methods of use